Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
Background: Everolimus is one of the key drugs for the treatment of advanced breast cancer. The optimal target concentration range for everolimus therapy in patients with breast cancer has not yet been established. This study aimed to characterize everolimus pharmacokinetics (PK) and determine the r...
Saved in:
Main Authors: | Masaki Hirabatake (Author), Tomoyuki Mizuno (Author), Hironori Kato (Author), Tohru Hashida (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
by: Masaki Hirabatake, et al.
Published: (2022) -
Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles
by: Marc Labriffe, et al.
Published: (2022) -
Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling
by: Matthijs W. van Hoogdalem, et al.
Published: (2024) -
Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study
by: Shinya Takasaki, et al.
Published: (2019) -
Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
by: Arianna Bonizzi, et al.
Published: (2019)